Physician profile
Jeffrey Kwan
NPI 1851439848
$3,086.35
in general payments reported to CMS, 2019-2025
25 companies · $1,470 in 2025
The $1,470 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18.74 · 2021: $81.64 · 2022: $242 · 2023: $613 · 2024: $662 · 2025: $1,470.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,744.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,744.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $829.46 | 2022-2025 | |
| Ardelyx, INC. | $423.83 | 2023-2025 | Ibsrela |
| Qol Medical, LLC | $292.84 | 2023-2025 | Sucraid, Sucraid |
| Takeda Pharmaceuticals U.S.A., INC. | $279.32 | 2019-2025 | Entyvio, Gattex, Eohilia |
| Celgene Corporation | $244.08 | 2021-2024 | Zeposia |
| Aimmune Therapeutics, INC. | $158.46 | 2025 | Zenpep, Vowst |
| Braintree Laboratories, INC. | $115.34 | 2022-2025 | Sutab, Suflave |
| Janssen Biotech, INC. | $90.22 | 2023-2024 | Stelara, Simponi, Simponi Aria |
| Medtronic, INC. | $69.08 | 2025 | Barrx |
| Gilead Sciences, INC. | $69.05 | 2023-2025 | |
| Pfizer INC. | $66.73 | 2023-2025 | |
| Exact Sciences Corporation | $51.99 | 2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $50.84 | 2024-2025 | Omvoh |
| E.R. Squibb & Sons, L.L.C. | $43.80 | 2021 | |
| Fresenius Kabi USA, LLC | $42.82 | 2023-2024 | Idacio |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ferring Pharmaceuticals INC. | $41.86 | 2023-2024 | Rebyota |
| Regeneron Healthcare Solutions, INC. | $36.92 | 2024 | Dupixent |
| Evoke Pharma, INC. | $36.58 | 2024-2025 | |
| Madrigal Pharmaceuticals | $25.22 | 2025 | Rezdiffra |
| Mirum Pharmaceuticals, INC. | $25.21 | 2025 | Chenodal, Cholbam, Livmarli |
| Intercept Pharmaceuticals, INC. | $21.96 | 2023 | Ocaliva |
| Vivus LLC | $19.79 | 2025 | Pancreaze |
| Genzyme Corporation | $19.09 | 2025 | |
| Ironwood Pharmaceuticals, INC | $17.67 | 2024 | |
| Phathom Pharmaceuticals, INC. | $14.19 | 2025 | Voquezna |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kwan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.